Hong Kong United Oncology Centre

Kowloon 00000

1 studies enrolling now · 6 studies all time

What they study most

ALK+ Advanced NSCLC, Advanced Non Small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer, HER2 Mutation, EGFR Mutation, HER2 Mutation, Locally Advanced or Metastatic Unresectable Urothelial Cancer, Metastatic Non Small Cell Lung Cancer, Non-Small-Cell Lung Cancer

Studies at this site

• A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) — Recruiting now
• First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) — Recruiting now
• Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread — Completed
• CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC — Completed
• A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer — Completed
• Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation — Running, not enrolling